Patients ( n = 60 ) were randomized ( 1:1 ) to receive rituximab ( 375 mg/m ( 2 ) intravenously [ I.V. ] weekly for 4 weeks ) either as a single agent or with bevacizumab ( 10 mg/kg I.V. on days 3 and 15 ) .